PMOS vs. PCOS: What the Name Change Means for Your Fertility
In May 2026, polycystic ovary syndrome (PCOS) was renamed polyendocrine metabolic ovarian syndrome (PMOS). The change followed a global consensus process published in The Lancet. The condition affects one in eight reproductive-aged women, more than 170 million people worldwide.
For patients trying to conceive, the practical question is whether the new name changes diagnosis or treatment. It does not. The 2026 International Guideline Terminology Update from Monash University states that the guideline’s recommendations and content remain unchanged.
Damien Fertility Partners has treated ovulatory disorders, including PMOS, across New Jersey since 1989. Our two board-certified reproductive endocrinologists see patients in Shrewsbury, Newark, and Jersey City. The same physician stays with you from the first consultation through every monitoring visit and procedure.
The Name and the Condition Are Separate
The clearest way to understand the change is to separate the name from the condition and its evidence-based management. Only the name is new. The condition and the way it is diagnosed and treated remain the same.
Changes in the 2026 Terminology Update
In May 2026, the international guideline was updated to use PMOS. The introduction and several appendices now use PMOS alone. The recommendations and algorithms use “PMOS/PCOS” because all evidence synthesis was completed when the condition was still called PCOS.
The next full guideline, due in 2028, will use PMOS exclusively. Until then, PMOS and PCOS will coexist during a three-year managed transition.
Diagnosis and Treatment Unchanged
For clinicians, the guideline update states that clinical features, diagnostic criteria, and management remain unchanged. A previous PCOS diagnosis does not become a different diagnosis because the terminology changed.
A new PMOS-specific sequence has not replaced fertility treatment. The 2023 International Evidence-based Guideline, published in the Journal of Clinical Endocrinology & Metabolism, still sets the treatment order.
The real difference is emphasis. The new name makes the endocrine and metabolic dimensions of the condition explicit. It reflects care that spans reproductive, metabolic, cardiovascular, dermatologic, sleep, and psychological health, not fertility alone.
The Rationale for Renaming PCOS
The old name dates to the 1930s and was based on a surgical finding. Decades of research have since shown that the condition extends well beyond the ovaries.
The Problem With “Polycystic”
Pathological ovarian cysts are not a feature of the condition. The appearance on ultrasound reflects arrested follicle development, not cyst formation.
The narrow ovarian focus has had real consequences. Up to 70% of affected individuals remain undiagnosed, according to the Monash University terminology update. The reproductive-centered name also obscured the condition’s metabolic and cardiovascular features, which fragmented care.
The 14-Year Consensus Process
The process took 14 years and engaged 56 professional and patient organizations. It was led by Monash University’s Centre for Health Research and Implementation, the Androgen Excess and PMOS Society, and Verity, a UK patient advocacy group.
Global surveys drew 22,000 responses from all world regions. Among respondents, 86% of people with the condition and 71% of health professionals supported an accurate, symptom-based name. The Endocrine Society was among the participating organizations. The American Society for Reproductive Medicine (ASRM) endorsed the new name on May 27, 2026.
The Meaning Behind Each Word in PMOS
Polyendocrine. Multiple hormone systems interact: elevated androgens, increased GnRH pulsatility and LH, and insulin resistance. Insulin resistance is present in approximately 85% of people with PMOS.
Metabolic. Insulin resistance, central weight gain, type 2 diabetes, abnormal lipids, and hypertension are core features. The odds of cardiovascular disease, heart attack, and stroke are significantly elevated.
Ovarian. Ovarian dysfunction remains a defining feature. It drives irregular ovulation, elevated anti-Müllerian hormone (AMH), and infertility.
Syndrome. PMOS is a cluster of features, not a single-cause disease, and it presents differently from patient to patient.
PMOS and PCOS in Your Medical Records
You may see both names on lab reports, referral letters, and insurance paperwork until 2029. ASRM has already retitled its summary of the 2023 guideline recommendations under the PMOS name.
Billing codes follow a separate process. Formal engagement with the World Health Organization to integrate PMOS into the International Classification of Diseases (ICD) is underway. Until that is complete, the diagnosis code on your chart may not change.
None of this requires action from you. An existing diagnosis carries forward under the new name.
PMOS Diagnostic Criteria
The diagnostic framework is unchanged. It builds on the Rotterdam criteria, updated to evidence-based criteria in the 2023 guideline.
Criteria for Adults
Adults are diagnosed when at least two of three features are present, after other causes are excluded:
- Clinical or biochemical hyperandrogenism (elevated androgens, or signs such as excess hair growth)
- Ovulatory dysfunction or irregular cycles
- Polycystic ovarian morphology on ultrasound, or elevated AMH
On transvaginal ultrasound, the threshold is 20 or more follicles in at least one ovary. AMH or ultrasound may be used to define ovarian morphology, but the guideline advises against performing both, to limit overdiagnosis.
Diagnosis Without Ultrasound or AMH
When irregular cycles and hyperandrogenism are already present, neither ultrasound nor AMH is required for diagnosis. In adolescents, both features are required, and ultrasound and AMH are not recommended within eight years of the first period.
Conditions We Rule Out
The guideline recommends excluding thyroid disease (TSH), elevated prolactin, and non-classic congenital adrenal hyperplasia (17-hydroxyprogesterone). Our evaluation and diagnosis process includes these tests.
It also covers metabolic screening. The guideline recommends a lipid profile at diagnosis and blood pressure measurement when seeking fertility treatment.
PMOS and Ovulatory Infertility
PMOS interferes with regular ovulation. Without predictable ovulation, there are fewer opportunities to conceive each year. For a patient-level overview, see our post on common PCOS myths.
Ovulation Is Treatable
Most patients with PMOS ovulate with medication, and many conceive without IVF. The guideline’s own framing emphasizes good general reproductive potential, acknowledging that some medical assistance may be required.
Metabolic Health Before Conception
The guideline recommends an oral glucose tolerance test (OGTT) for all patients with PMOS who are planning pregnancy or seeking fertility treatment. The concern is the high risk of elevated blood sugar in pregnancy.
PMOS is also considered a high-risk condition in pregnancy, and patients should be identified and monitored. Our post on causes and risk factors for miscarriage covers related considerations. The guideline also recommends screening for depression and anxiety in all adults with PMOS.
Weight and Access to Care
We place no BMI-based limitations on care. The guideline itself calls for minimizing weight stigma, asking permission before weighing, and offering best-practice treatment regardless of weight.
Weight can be discussed as one factor in treatment response. It does not determine whether you can begin treatment with our practice. Read more about our diversity and inclusion commitments.
Fertility Treatment for PMOS, Step by Step
For anovulatory infertility without other infertility factors, the guideline sets out a clear sequence. We follow it while adjusting to each patient’s history, response, and goals.
Lifestyle and metabolic support. The guideline recommends healthy lifestyle support for all patients with PMOS, with no single diet shown to outperform others. Inositol offers limited clinical benefit, as discussed in our review of fertility supplements. For patients asking about weight medications, see our post on GLP-1 medications and fertility.
Letrozole (first line). Letrozole is the first-line medication for infertility associated with PMOS. It is an oral medication taken for five days early in the cycle. Our letrozole for fertility page explains how it works and why most specialists recommend three to six monitored cycles before changing protocols.
Monitoring and insemination. Every ovulation induction cycle is monitored with ultrasound and bloodwork. Cycles are often paired with timed intercourse or intrauterine insemination (IUI).
Second-line options. Clomiphene (alone or with metformin), injectable gonadotropins, and ovarian surgery serve as second-line therapy. Gonadotropins require close monitoring because PMOS ovaries can respond strongly.
IVF (third line). IVF, potentially with in vitro maturation of eggs, may be offered as third-line therapy when other ovulation induction has not succeeded. It moves earlier when there is another indication, such as blocked tubes, male factor infertility, or planned genetic testing.
IVF With PMOS
Patients with PMOS often produce many follicles during stimulation. That can mean more eggs. It also raises the risk of ovarian hyperstimulation syndrome (OHSS), in which the ovaries swell and fluid shifts into the abdomen.
Managing a Strong Ovarian Response
The guideline addresses stimulation protocol and trigger choice specifically for this population. Our IVF protocols for PMOS typically use a GnRH antagonist protocol. That allows a GnRH agonist trigger in place of hCG, which lowers OHSS risk.
Some patients benefit from freezing all embryos. The transfer then happens as a frozen embryo transfer (FET) in a later cycle, after the ovaries return to baseline.
Embryology Lab and CHLOE
A high egg yield means more embryos to evaluate. Our embryology laboratory holds accreditation from the College of American Pathologists (CAP), the FDA, and the NJ State Department of Health, all with zero deficiencies. See our accreditations for details.
Embryos develop in embryoscope time-lapse incubators with CHLOE by Fairtility, an AI-powered system that monitors development continuously. Patients considering embryo testing can read our overview of PGT-A and IVF.
In 2023, we reported a 100% elective single-embryo transfer rate among patients under 35, according to SART data. Clinic-to-clinic comparisons should be interpreted with caution due to differences in patient populations. Our success rates page gives full context.
Insurance Coverage in New Jersey
The name change does not by itself alter coverage. Coverage depends on your plan and your infertility diagnosis, not on which name appears in your records.
The State Mandate
New Jersey first required infertility coverage in 2001. That original mandate included up to four completed egg retrievals per lifetime, according to the NJ Department of Banking and Insurance.
On January 12, 2024, Governor Murphy signed A5235/S3627. The law applies to state-regulated insurers providing pregnancy-related benefits to groups of more than 50 people. It requires coverage for infertility services in line with ASRM guidelines, including IVF, IUI, genetic testing, and embryo transfers.
Plans Covered by the Mandate
The mandate applies to fully insured plans. Self-insured employers are exempt, according to ReproductiveFacts.org, ASRM’s patient resource.
Our bilingual Insurance Verification Specialist confirms your benefits before treatment begins. For costs outside coverage, CapexMD financing offers 24-hour pre-approval. See our insurance and financial resources page.
PMOS Care at Our New Jersey Offices
We diagnose and treat PMOS at our three offices: Shrewsbury (Monmouth County), Newark (Essex County), and Jersey City (Hudson County). Spanish-speaking providers are available at all three locations, and our site is available in Spanish.
Dr. Miguel Damien founded the practice in 1989 and completed fellowships in reproductive endocrinology and infertility at Harvard Medical School and the University of Connecticut. Dr. Barry Perlman completed his fellowship at Rutgers New Jersey Medical School, and PMOS is among his clinical interests. Dr. Seigelstein handles surgical evaluation in-house, and our Nurse Practitioners manage monitoring and in-office procedures.
Virtual consultations are available with Dr. Perlman. To learn what the first visit involves, see How to Begin, or read more about choosing a fertility clinic in New Jersey.
Request a consultation with Dr. Damien or Dr. Perlman to review your diagnosis and discuss your treatment options.
Frequently Asked Questions
Is PMOS the same condition as PCOS?
Yes. PMOS is the new name for the condition previously called PCOS. The 2026 terminology update states that the guideline’s recommendations and content remain unchanged.
Do I need to be re-diagnosed if I was told I have PCOS?
No. An existing PCOS diagnosis remains valid under the new name. Your records may show PCOS, PMOS, or “PMOS/PCOS” during the three-year transition.
Can I have PMOS without ovarian cysts?
Yes. True cysts are not a feature of the condition. Patients with irregular cycles and elevated androgens can be diagnosed without any ultrasound or AMH testing. See our evaluation and diagnosis page.
What is the first fertility treatment for PMOS?
Letrozole is the first-line medication for anovulatory infertility without other infertility factors. It is usually paired with monitoring and timed intercourse or IUI. Our letrozole for fertility page covers the process.
Will the name change affect my insurance coverage in New Jersey?
No. Coverage under New Jersey’s mandate depends on your plan type and your infertility diagnosis, not the condition’s name. Our Insurance Verification Specialist can confirm your benefits; see our insurance and financial resources page.
Do you have BMI requirements for PMOS fertility treatment?
No. We place no BMI-based limitations on care. Read more about our diversity and inclusion commitments.